Drug Profile
REV 123
Latest Information Update: 13 Sep 2006
Price :
$50
*
At a glance
- Originator Novartis
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 13 Sep 2006 Discontinued - Phase-I for HIV infections treatment in South America (unspecified route)
- 13 Sep 2006 Discontinued - Phase-II for HIV infections treatment in USA (unspecified route)
- 27 Feb 2001 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)